Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

PeptiDream, Ipsen expand research collaboration
November 2013
SHARING OPTIONS:

TOKYO—PeptiDream and Ipsen have announced the expansion of their research collaboration and license option agreement. The agreement was initiated in April for the discovery, evaluation, potential development and launch of therapeutic peptides to treat medical conditions in areas of interest to Ipsen, and will now be expanded to allow additional therapeutic peptide candidates for endocrinologic disease. Financial terms were not disclosed, but Ipsen will be responsible for all R&D and commercialization costs, while PeptiDream will either receive royalties on worldwide sales or have the right to opt-in at predetermined stages to support Japan development costs of each new candidate in return for royalty-free commercial rights in that territory. Should PeptiDream exercise that right, it would also waive royalty income for ex-Japan sales.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.